Congressional Panel to Consider FDA Drug Safety Bill

Happens today. According to reports, a U.S. House of Representatives subcommittee will take up legislation that gives teeth to the FDA's ability to monitor prescription drug side effects post drug approval.

A draft of the bill includes parts that are tougher than those passed in a similar Senate bill. One section limits consumer drug advertisements and symbols on newly approved medications to alert patients.

Source here.